Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06929455 · ClinicalTrials.gov registry record · NA

Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines

A NA study of Healthy Adults, sponsored by Monell Chemical Senses Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06929455: Recruiting NA study of Healthy Adults, sponsored by Monell Chemical Senses Center.

NCT06929455 is a NA study of Healthy Adults that is actively recruiting participants, run by Monell Chemical Senses Center. The registered enrollment target is 100 participants, above the 83-participant average among 33 other Healthy Adults trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06929455, a NA study of Healthy Adults, is actively recruiting participants, sponsored by Monell Chemical Senses Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Many people, particularly small children, must take drugs in liquid form because they cannot swallow pills or capsules. The bad taste of some liquid drugs can keep patients from taking drugs they need for their health. Our main goal in this research study is find ingredients that might make drugs taste better. Participants in this research study will be healthy adults between the ages of 18 and 60 years old. Participants will taste samples (liquids or gels) containing active pharmaceutical ingredients (substances in medications that produce desired health effects). After tasting each sample participants will spit out the sample and rinse with water (no samples will be swallowed). Active pharmaceutical ingredients of current interest are: 1) tenofovir alafenamide, used to treat HIV infection and hepatitis B, 2) rifampicin, used to treat tuberculosis, 3) rifapentine, used to treat tuberculosis, and 4) levofloxacin, used to treat various bacterial infections). Other active pharmaceutical ingredients may be added as the study goes forward. Participants will be instructed to taste samples both with and without experimental flavor ingredients added and judge how the samples taste. People who volunteer for the study will be instructed to complete many repeated visits to the Monell Center (University City area of Philadelphia) for tasting sessions. Tasting visits will last between 1 and 2 hours.

Primary Outcome

Ratings of oral sensation (e.g., bitterness, sourness, astringency, etc.) made using the general Labeled Magnitude Scale. Values range from 0 (no sensation) to 100 (strongest imaginable sensation)

Conditions Studied

Interventions

  • OTHER Flavor additives

Study Locations (1)

Pennsylvania

  • Monell Chemical Senses Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-03-18
Est. Completion 2026-11-01
Phase NA
Monell Chemical Senses Center

16 total trials

What NCT06929455 shows while recruiting

NCT06929455 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 33 other Healthy Adults trials with a reported enrollment target (20% higher).

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 1 intervention - of which Flavor additives is the first listed.

NCT06929455 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06929455 about?

NCT06929455 is a clinical study titled "Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines". Many people, particularly small children, must take drugs in liquid form because they cannot swallow pills or capsules. The bad taste of some liquid drugs can keep patients from taking drugs they need for their health. Our main goal in this research study is find ingredients that might make drugs ta...

What is the current status of trial NCT06929455?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-03-18. Estimated completion is 2026-11-01.

What conditions does trial NCT06929455 study?

This clinical trial studies the following conditions: Healthy Adults.

What interventions are being tested in trial NCT06929455?

The interventions under investigation include: Flavor additives (OTHER).

Who is sponsoring clinical trial NCT06929455?

This trial is sponsored by Monell Chemical Senses Center, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06929455 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06929455's enrollment target sits among peer trials

100 6th of 33 higher than 27 of 33 other Healthy Adults trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06929455, the US trial registry maintained by the National Library of Medicine. NCT06929455 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.